Holen Sie sich die Stockscreener-App
2.11
6.64%
-0.15
Handel nachbörslich:
2.11
Schlusskurs vom Vortag:
$2.26
Offen:
$2.17
24-Stunden-Volumen:
86,125
Relative Volume:
0.03
Marktkapitalisierung:
$9.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-125.52M
KGV:
-0.2796
EPS:
-7.5468
Netto-Cashflow:
$-5.72M
1W Leistung:
+5.42%
1M Leistung:
-14.95%
6M Leistung:
-79.55%
1J Leistung:
+0.00%
1-Tages-Spanne:
$2.02
$2.19
1-Wochen-Bereich:
$1.7488
$2.40
52-Wochen-Spanne:
$1.2104
$13.28
Lunai Bioworks Inc Stock (LNAI) Company Profile
Firmenname
Lunai Bioworks Inc
Sektor
Branche
Telefon
45 39179840
Adresse
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare LNAI vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNAI
Lunai Bioworks Inc
|
2.11 | 10.25M | 0 | -125.52M | -5.72M | -7.5468 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lunai Bioworks Inc Aktie (LNAI) Neueste Nachrichten
Lunai Bioworks, Inc. Financial Disclosures & SEC Filings - TradingView
Lunai Bioworks Heads Into Key Week After Reverse Split, Ongoing Court Battle - Bez Kabli
Lunai Bioworks to implement 1-for-8 reverse stock split - MSN
Lunai Bioworks Inc. (LNAI) Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider-Than-Expected Loss Amid Pipeline ProgressEnergy Earnings Report - Newser
Lunai Bioworks federal judge grants Lunai Bioworks expedited discovery to identify "naked" short sellers - marketscreener.com
Lunai Bioworks Federal Judge Grants Lunai Bioworks Expedited Discovery To Identify "Naked" Short Sellers - TradingView
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock - PR Newswire
Lunai Bioworks Inc. (LNAI) Q1 2026 Earnings: Early-Stage Biotech Delivers Strategic Progress Despite GAAP LossTrending Volume Leaders - Newser
LNAI Should I Buy - Intellectia AI
Lunai Bioworks (LNAI) Q1 2026 Earnings: As Expected, No SurprisesEarnings Volatility Report - Newser
Lunai Bioworks Announces 1-for-8 Reverse Stock Split - The Globe and Mail
Lunai Bioworks Announces 1-for-8 Reverse Stock Split to Regain Nasdaq Compliance - Minichart
Lunai Bioworks stock falls after reverse split announcement By Investing.com - Investing.com South Africa
Lunai Bioworks announces 1-for-8 reverse stock split By Investing.com - Investing.com Australia
Lunai Bioworks announces 1-for-8 reverse stock split - Investing.com
Lunai Bioworks, Inc. Announces Reverse Stock Split - TradingView
Lunai Bioworks stock falls after reverse split announcement - Investing.com
Lunai Bioworks announces 1-for-8 reverse stock split to boost Nasdaq compliance, shares cut to ~4.53M - TradingView
Lunai Bioworks (NASDAQ: LNAI) plans 1-for-8 reverse split to meet Nasdaq price rule - Stock Titan
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT - PR Newswire
Dickinson Wright And Fox Rothschild Join Forces To File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers Of Lunai Common Stock - marketscreener.com
LNAI Stock Chart | LUNAI BIOWORKS INC (NASDAQ:LNAI) - ChartMill
Lunai Bioworks: Fiscal Q3 Earnings Snapshot - 10TV
Lunai Bioworks Inc. 3Q 2026: Revenue $20942 Net loss $(2.57M), EPS $(0.10) — 10-Q Summary - TradingView
[10-Q] Lunai Bioworks Inc. Quarterly Earnings Report - Stock Titan
Lunai Bioworks Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Lunai Bioworks Shareholders Approve Flexible Reverse Stock Split - The Globe and Mail
Lunai Bioworks Inc approves reverse stock split at ratio of 1-for-3 to 1-for-30SEC filing - marketscreener.com
Lunai Bioworks IncApproves Reverse Stock Split At Ratio Of 1-For-3 To 1-For-30SEC Filing - TradingView
Lunai Bioworks shareholders approve reverse stock split and meeting adjournment By Investing.com - Investing.com South Africa
Lunai Bioworks shareholders approve reverse stock split and meeting adjournment - Investing.com Nigeria
Lunai Bioworks (NASDAQ: LNAI) wins shareholder approval for reverse stock split - Stock Titan
Lunai Bioworks Files Securities Fraud Lawsuit Alleging Naked Short Selling Scheme - citybuzz -
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock - The Manila Times
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe’ ‘Naked’ Short-Sellers of Lunai Common Stock - GlobeNewswire Inc.
Lunai Bioworks (LNAI) warns of Nasdaq delisting risk after MVLS shortfall - Stock Titan
How Lunai Bioworks (LNAI) performance reflects its true potential (-0.90%) 2026-05-10Continuation Signals - newser.com
Why Lunai Bioworks (LNAI) might be the best kept secret in the market (At Lows) 2026-05-08Expert Momentum Signals - newser.com
Number of shareholders of Lunai Bioworks Inc. – NASDAQ:LNAI - TradingView
LNAI: Shareholders voted on a reverse stock split and adjournment proposal, both board-recommended - TradingView
The key trends fueling Lunai Bioworks (LNAI) growth potential (+6.29%) 2026-05-08Micro Trends - newser.com
Oncotelic Therapeutics Announces Closing of a Strategic - GlobeNewswire
Oncotelic Therapeutics Announces Closing of a Strategic Monetization of Its CNS/Nasal Assets with Lunai Bioworks, Advancing Joint Development in Biodefense and Alzheimer’s Disease - Yahoo Finance
Stock Market Today: Nasdaq, S&P 500 Futures Gain While Dow Slips Amid Israel-Lebanon Ceasefire Extension—Intel, SAP, Lunai Bioworks In Focus (UPDATED) - MSN
Oncotelic Therapeutics Completes Neurobridge IP Merger With Lunai Bioworks for $20M in Preferred Stock - TradingView
Lunai Bioworks Stock: $20 Million Patent Deal Puts Nasdaq Fight in Focus - TechStock²
Lunai Bioworks Completes $20 Million Preferred Equity Issuance - Intellectia AI
A $20M Lunai deal adds two routes past the blood-brain barrier - Stock Titan
Lunai Bioworks Inc. completed the acquisition of BBB delivery technology and CNS Alzheimer's drug assets of Clemann Group from Clemann Group. - marketscreener.com
Lunai Bioworks initiates employee furloughs and salary deferrals to preserve liquidity - Investing.com
Finanzdaten der Lunai Bioworks Inc-Aktie (LNAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):